Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
FLT3
Name:
fms related receptor tyrosine kinase 3
Location:
13q12.2
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT05115344 | Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors | View | |
| NCT04209725 | A Study of CPX-351 Vyxeos With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | View | |
| NCT00731744 | Generation of Dendritic Cell Precursors From Cord Blood Stem Cells | View | |
| NCT01296178 | PETHEMA-LMA10 Treatment of Acute Myeloblastic Leukemia AML in Patients Less Than or Equal to 65 Years | View | |
| NCT01436084 | SB1518 for Patients With Myelodysplastic Syndrome MDS | View | |
| NCT04240002 | A Study of Gilteritinib ASP2215 Combined With Chemotherapy in Children Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 FLT3Internal Tandem Duplication ITD Positive Relapsed or Refractory Acute Myeloid Leukemia AML | View | |
| NCT03690115 | Study of Ponatinib Iclusig for Prevention of Relapse After Allogeneic Stem Cell Transplantation Allo-SCT in FLT3-ITD AML Patients | View | |
| NCT02272478 | Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | View | |
| NCT02298166 | Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations | View | |
| NCT02829840 | Dose-Escalation Study of Ponatinib a FLT3 Inhibitor With and Without Combination of 5-Azacytidine in Patients With FLT3-Mutated Acute Myeloid Leukemia AML | View | |
| NCT02428543 | Ponatinib for FLT3-ITD Acute Myelogenous Leukemia | View | |
| NCT05599360 | Vyxeos for Induction of Low- or Intermediate-risk | View | |
| NCT03097601 | ELRCXCL Cytokines in Metastatic Kidney Cancers Predictive Markers of Resistance to Sunitinib | View | |
| NCT03280888 | Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia CMML | View | |
| NCT04278768 | Dose Escalation Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia AML or Myelodysplastic Syndrome MDS | View | |
| NCT03425201 | Niraparib in Combination With Cabozantinib XL184 in Patients With Advanced Urothelial Cancer NICARAGUA | View | |
| NCT04174612 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance | View | |
| NCT01462474 | Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma | View | |
| NCT04641910 | Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia | View | |
| NCT00019396 | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | View | |
| NCT04946890 | A Study of MRX2843 in Subjects With RelapsedRefractory Acute Myeloid Leukemia | View | |
| NCT05153343 | Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | View | |
| NCT05219266 | Managed Access Programs for PKC412 Midostaurin | View | |
| NCT05241093 | A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia AML | View | |
| NCT05339204 | The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission | View | |
| NCT05541224 | A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers | View | |
| NCT00006223 | flt3L in Treating Patients With Acute Myeloid Leukemia | View | |
| NCT06235801 | A Phase III Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | View | |
| NCT02450877 | A Study of Safety Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia | View | |
| NCT06303193 | Pacritinib a Kinase Inhibitor of CSF1R IRAK1 JAK2 and FLT3 in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or MyelodysplasticMyeloproliferative Neoplasms | View | |
| NCT04015024 | A Clinical Study of SKLB1028 Capsule in the Treatment of RecurrenceRefractory AML Patients | View | |
| NCT01141673 | Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia | View | |
| NCT00469859 | Lestaurtinib Cytarabine and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | View | |
| NCT01253070 | Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | View | |
| NCT00373373 | Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | View | |
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD Acute Myeloid Leukemia AML | View | |
| NCT04385290 | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia MOSAIC | View | |
| NCT01440959 | Dovitinib for ImatinibSumitinib-failed Gastrointestinal Stromal Tumors GIST TKI258 | View | |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | View | |
| NCT01477606 | Protocol in Acute Myeloid Leukemia With FLT3-ITD | View | |
| NCT04477291 | A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | View | |
| NCT03900949 | Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | View | |
| NCT02624570 | Midostaurin Access Program for Newly Diagnosed FLT3 ITD or TKD Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy | View | |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | View | |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin PKC412 in Relapsed or Refractory Pediatric Leukemia | View | |
| NCT02310321 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | View | |
| NCT00943943 | Granulocyte-colony Stimulating Factor G-CSF and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia AML With FLT3 Mutations | View | |
| NCT00989261 | Efficacy Study for AC220 to Treat Acute Myeloid Leukemia AML | View | |
| NCT01004861 | Safety Study of PLX108-01 in Patients With Solid Tumors | View | |
| NCT01217229 | Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma | View | |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | View | |
| NCT04674345 | Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia | View | |
| NCT02859948 | A Study of SKLB1028 in Subjects With RelapsedRefractory Acute Myeloid Leukemia | View | |
| NCT00542971 | Phase I-II Study of Idarubicin Cytarabine and Sorafenib BAY43-9006 | View | |
| NCT04752527 | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features | View | |
| NCT02364362 | A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC | View | |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 andor Ras Mutations | View | |
| NCT04796831 | A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects | View | |
| NCT01762293 | A Study of Famitinib in Patients With Advanced Colorectal Cancer | View | |
| NCT01349049 | Phase 12 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia AML | View | |
| NCT04817241 | Testing Oral Decitabine and Cedazuridine ASTX727 in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | View | |
| NCT01398501 | Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant | View | |
| NCT02400255 | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients | View | |
| NCT02400281 | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | View | |
| NCT01468467 | A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia AML | View | |
| NCT01470638 | A Study of Flt3-Ligand Levels in Sjögrens Syndrome | View | |
| NCT01486732 | FLT-PET Activity Change After Allogeneic Umbilical Cord Blood UCB Therapy in Cerebral Palsy | View | |
| NCT02839265 | FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer | View | |
| NCT02421939 | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia AML With FMS-like Tyrosine Kinase FLT3 Mutation | View | |
| NCT01522469 | Phase II Study of Crenolanib in Subjects With RelapsedRefractory AML With FLT3 Activating Mutations | View | |
| NCT01565668 | Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | View | |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | View | |
| NCT01657682 | A Phase II Study of Crenolanib in RelapsedRefractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations | View | |
| NCT05029999 | CD40 Agonist Flt3 Ligand and Chemotherapy in HER2 Negative Breast Cancer | View | |
| NCT04140487 | Azacitidine Venetoclax and Gilteritinib in Treating Patients With RecurrentRefractory FLT3-Mutated Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia or High-Risk Myelodysplastic SyndromeMyeloproliferative Neoplasm | View | |
| NCT03070093 | Expanded Access Study of Gilteritinib ASP2215 in Patients With FMS-like Tyrosine Kinase 3 FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia AML or FLT3-Mutated AML in Complete Remission CR With Minimal Residual Disease MRD | View | |
| NCT02997202 | A Trial of the FMS-like Tyrosine Kinase 3 FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3Internal Tandem Duplication ITD Acute Myeloid Leukemia AML | View | |
| NCT01829841 | A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer | View | |
| NCT05143996 | CLN-049 in Patients With RelapsedRefractory Acute Myeloid Leukemia AML or Myelodysplastic Syndrome MDS | View | |
| NCT01846624 | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | View | |
| NCT01883362 | Standard of Care - Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML | View | |
| NCT05199051 | A Phase 2 Study of Gemtuzumab Ozogamicin GO-Gilteritinib Combination in Adults With FLT3-ITD RelapseRefractory RR AML | View | |
| NCT03170895 | Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or RelapsedRefractory AML Carrying FLT3-ITD | View | |
| NCT02039726 | QuANTUM-R An Open-label Study of Quizartinib Monotherapy vs Salvage Chemotherapy in Acute Myeloid Leukemia AML Subjects Who Are FLT3-ITD Positive | View | |
| NCT05313958 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | View | |
| NCT02129075 | A Vaccine CDX-1401 With or Without a Biologic Drug CDX-301 for the Treatment of Patients With Stage IIB-IV Melanoma | View | |
| NCT03250338 | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in RR FLT3 Mutated AML | View | |
| NCT03409081 | Early Access Program EAP of Gilteritinib ASP2215 in Patients With FMS-like Tyrosine Kinase 3 FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia AML or With FLT3-Mutated AML in Complete Remission CR With Minimal Residual Disease MRD | View | |
| NCT03280030 | A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | View | |
| NCT05445011 | Anti-FLT3 CAR-T Cell TAA05 Cell Injection in the Treatment of Relapsed Refractory Acute Myeloid Leukemia | View | |
| NCT02283177 | A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | View | |
| NCT02323607 | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | View | |
| NCT02336724 | A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor | View | |
| NCT02356991 | A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC | View | |
| NCT05596968 | The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT | View | |
| NCT05601895 | The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance | View | |
| NCT02474290 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | View | |
| NCT03552029 | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia AML | View | |
| NCT03730012 | A Study of ASP2215 Gilteritinib Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase FLT3 Mutated Acute Myeloid Leukemia AML | View | |
| NCT03591510 | A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | View | |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | View | |
| NCT02626338 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With RR AML | View | |
| NCT05713279 | Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus COVID-19 Infection | View | |
| NCT03620318 | Individual Patient Compassionate Use of Crenolanib | View | |
| NCT02693899 | Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia | View | |
| NCT05756777 | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia AML | View | |
| NCT02723435 | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | View | |
| NCT02789254 | FLYSYN in MRD Positive AML | View | |
| NCT02867891 | Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 FLT3-Internal Tandem Duplication ITD AML Trial | View | |
| NCT04293562 | A Study to Compare Standard Chemotherapy to Therapy With CPX-351 andor Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | View | |
| NCT04311060 | Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia a Prospective Multicentric Study | View | |
| NCT02984995 | Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia AML FLT3 Internal Tandem Duplication FLT3ITD Mutation | View | |
| NCT05947344 | A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia AML | View | |
| NCT03047083 | Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia AML With or Without FMS-like Tyrosine Kinase-3 FLT3 Mutation Study Based on Retrospective Chart Review | View | |
| NCT01831726 | Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | View | |
| NCT04491084 | FLT3 Ligand CD40 Agonist Antibody and Stereotactic Radiotherapy | View | |
| NCT03114228 | An Expanded Treatment Protocol ETP of Midostaurin PKC412 in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia AML | View | |
| NCT01830361 | Trial to Assess the Efficacy of Midostaurin PKC412 in Patients With c-KIT or FLT3-ITD Mutated t821 AML | View | |
| NCT03125876 | A Phase Ib Study of CT053PTSA in Relapsed Refractory Acute Myeloid Leukemia AML | View | |
| NCT03135054 | Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD | View | |
| NCT06022003 | Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects 18 Years of Age With RelapsedRefractory FLT3-mutated Acute Myeloid Leukemia | View | |
| NCT05330377 | GM-CLAG in RelapsedRefractory FLT3-mutated AML | View | |
| NCT03182244 | A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia AML With FLT3 Mutation | View | |
| NCT03194685 | Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | View | |
| NCT03315299 | Individual Patient Expanded Access Gilteritinib ASP2215 | View | |
| NCT03324243 | A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With RelapsedRefractory FLT3-Mutated Acute Myeloid Leukemia | View | |
| NCT03379727 | Study to Assess the Safety and Efficacy of Midostaurin PKC412 in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 FLT3 Kinase Receptor-mutated Acute Myeloid Leukemia | View | |
| NCT06211452 | Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia | View | |
| NCT04676243 | Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physicians Choice in Newly Diagnosed FLT3-ITD AML | View | |
| NCT03547258 | Italian Non-Interventional Study of FLT3 Mutated AML Patients | View | |
| NCT04842370 | Evaluation of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of PHI 101 for the Treatment of AML | View | |
| NCT06325748 | SENTI-202 Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 andor FLT3 Blood Cancers Including AMLMDS | View | |
| NCT03735875 | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia | View | |
| NCT03746912 | Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia AML to Receive Quizartinib | View | |
| NCT03760445 | HDM201 Added to CT in RR or Newly Diagnosed AML | View | |
| NCT06439199 | Biological Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy | View | |
| NCT03904069 | Study Evaluating the Safety Tolerability and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive RelapsedRefractory AML | View | |
| NCT03922100 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | View | |
| NCT05193448 | A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed RR FLT3 Mutated Acute MyEloid Leukemia AML Patients Treated With Gilteritinib in FrANCE | View | |
| NCT06463639 | FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia | View | |
| NCT05010122 | ASTX727 Venetoclax and Gilteritinib for the Treatment of Newly Diagnosed Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | View | |
| NCT04107727 | Trial to Compare Efficacy and Safety of ChemotherapyQuizartinib vs ChemotherapyPlacebo in Adults FMS-like Tyrosine Kinase 3 FLT3 Wild-type Acute Myeloid Leukemia AML | View | |
| NCT06561880 | The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation | View | |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | View | |
| NCT05432401 | TAA05 Injection in the Treatment of Adult Patients With FLT3-positive RelapsedRefractory Acute Myeloid Leukemia | View | |
| NCT04473664 | A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment | View | |
| NCT04493138 | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or MyelodysplasticMyeloproliferative Neoplasm With FLT3 or CBL Mutations | View | |
| NCT04496999 | HDM201 and Midostaurin HDMM in RelapsedRefractory AML With FLT3mut and TP53wt | View | |
| NCT04518345 | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | View | |
| NCT05791890 | GilteRInf 2022 Study Gilteritinib Related Infections | View | |
| NCT02530476 | Phase III Study of Selective Inhibitor of Nuclear Export SINE Selinexor KPT-330 Sorafenib in Acute Myeloid Leukemia | View | |
| NCT04691648 | A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia AML With FMS-Like Tyrosine Kinase 3 FLT3 Mutation | View | |
| NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory RR AML With FLT3-Mutated | View | |
| NCT04747470 | Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors | View | |
| NCT04788420 | Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML | View | |
| NCT06222580 | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | View | |
| NCT04827069 | A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid LeukemiaAML | View | |
| NCT05017883 | TAA05 Cell Injection in the Treatment of Recurrent Refractory Acute Myeloid Leukemia | View | |
| NCT05028751 | A Study to Evaluate Lanraplenib LANRA in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia AML | View | |
| NCT05024552 | Vyxeos Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated AML | View | |
| NCT05023707 | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive RelapsedRefractory Acute Myeloid Leukemia | View | |
| NCT06313437 | Revumenib in Combination With 73 Midostaurin in AML | View | |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | View | |
| NCT05300438 | Phase I Study of TSN084 in Patients With Advanced Malignant Tumors | View | |
| NCT06648512 | Association of Ex Vivo Drug Response EVDR and Clinical Outcome in Acute Myeloid Leukaemia EXCYTE-2 | View | |
| NCT06649227 | Study Investigating the Safety of CD19 CAR-T Cells in RelapsedRefractory AML Expressing CD19 | View | |
| NCT05383014 | FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia | View | |
| NCT06611839 | Venetoclax and Ivosidenib Combined with Chemotherapy in IDH1 Mutated AML | View | |
| NCT05520567 | A Study of Gilteritinib Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | View | |
| NCT01945164 | XL999 Administered Intravenously to a Subject With Advanced Malignancies | View | |
| NCT00651261 | Daunorubicin Cytarabine and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | View | |
| NCT05546580 | Study of Iadademstat and Gilteritinib in Patients With RR AML With FMS-like Tyrosine Kinase Mutation FLT3 Mut | View | |
| NCT05586074 | HEC73543 Versus Salvage Chemotherapy in RR FLT3-ITD AML | View | |
| NCT05596981 | The Gut Microbiome in FLT3-ITD AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT | View | |
| NCT00783653 | Clinical Study of SU 11248 Sutent Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years | View | |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation ALIVE | View | |
| NCT05918692 | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | View | |
| NCT06652685 | Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | View | |
| NCT00557193 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | View | |
| NCT01150669 | Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia | View | |
| NCT06262438 | CHIP-AML22Quizartinib Quizartinib Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD and NPM1wt AML Patients | View | |
| NCT06317649 | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia AML A MyeloMATCH Treatment Trial | View | |
| NCT06366789 | Dose Escalation and Expansion Study to Evaluate the Safety PK PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia | View | |
| NCT01392235 | Famitinib in Treating Patients With Recurrent andor Metastatic Nasopharyngeal Carcinoma NPC | View | |
| NCT01390337 | A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia AML | View | |
| NCT06386705 | TSN084 Treating Patients With Advanced Malignant Tumors | View | |
| NCT06326502 | A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug ETN101 in Advanced Hepatocellular Carcinoma | View | |
| NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | View | |
| NCT02272998 | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes FGFR1 FGFR2 FGFR3 FGFR4 RET KIT | View | |
| NCT00003431 | Flt3L in Treating Patients With Metastatic Colorectal Cancer | View | |
| NCT06635681 | Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML | View | |
| NCT05241106 | A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia AML | View | |
| NCT02156297 | Sorafenib to Treat FLT3-ITD AML | View | |
| NCT03951961 | Midostaurin in MRD Minimal Residual Disease Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation | View | |
| NCT02196857 | Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia AML and High Risk Myelodysplastic Syndrome MS With FLT3-ITD Mutation | View | |
| NCT01161550 | Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in RelapsedRefractory AML | View | |
| NCT02390947 | Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal AdenocarcinomaFACT | View | |
| NCT01534260 | Phase III Study of Combination of Sorafenib Vorinostat and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk Monosomy 57 Cytogenetics or FLT3-ITD Positive Genotype | View | |
| NCT02752035 | A Study of ASP2215 Gilteritinib by Itself ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | View | |
| NCT02270788 | Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | View | |
| NCT00322673 | Study of XL999 in Patients With Acute Myeloid Leukemia AML | View | |
| NCT00045942 | PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome CPKC412A2104 Core and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 FLT3 CPKC412A2104E1 and CPKC412A2104E2 | View | |
| NCT00462761 | A Phase I Study of AC220 in Patients With RelapsedRefractory Acute Myeloid Leukemia Regardless of FLT3 Status | View | |
| NCT00553202 | Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7 -55q- High FLT3-ITD AR or Refractory or Relapsed Acute Myelogenous Leukemia | View | |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed Refractory or Poor Prognosis AML or MDS | View | |
| NCT00827138 | Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias Ph CML With T315I Mutation | View | |
| NCT00915252 | Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia AML | View | |
| NCT02675478 | Phase 1 Study of Quizartinib | View | |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in RelapsedRefractory Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma CLLSLL | View | |
| NCT02728050 | Filgrastim Cladribine Cytarabine and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | View | |
| NCT02861651 | Molecular Characterization of Acute Erythroid Leukemia M6-AML Using Targeted Next-generation Sequencing | View | |
| NCT02927262 | A Study of ASP2215 Gilteritinib Administered as Maintenance Therapy Following InductionConsolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 FLT3ITD Acute Myeloid Leukemia AML in First Complete Remission | View | |
| NCT03258931 | Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML | View | |
| NCT03311815 | Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing NGS in Patients Diagnosed With Acute Myeloid Leukemia | View | |
| NCT03329950 | A Study of CDX-1140 CD40 as Monotherapy or in Combination in Patients With Advanced Malignancies | View | |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative FLT3-MN Acute Myeloid Leukemia AML | View | |
| NCT03622541 | Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD | View | |
| NCT03642236 | Combination of BTK Inhibitor Overcomes Drug-resistance in RefractoryRelapsed FLT3 Mutant AML | View | |
| NCT03686345 | Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia | View | |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia AML a Cancer of the Blood | View | |
| NCT03836209 | Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | View | |
| NCT03989713 | Quizartinib and High-dose Ara-C Plus Mitoxantrone in RelapsedRefractory AML With FLT3-ITD | View | |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy | View | |
| NCT04097470 | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients | View |